Value proposition

Our vision: To profoundly impact the lives of patients with orphan diseases and their families

Orphazyme is a global biopharmaceutical company, headquartered in Denmark, with a rapidly growing presence in the United States. We are pioneering a new kind of treatment, applying our specialized expertise to bring innovative therapies to patients with neurodegenerative orphan diseases. With a late-stage drug pipeline, we are relentless in our commitment to advancing treatments and making a profound impact for those touched by these rare, serious diseases.

Today we are listed on Nasdaq Copenhagen (TICKER: ORPHA.CO) and Nasdaq U.S. (TICKER: ORPH), and are expanding our global presence with offices in Denmark, Switzerland, and our US headquarters in Chicago.

See our community guidelines: bit.ly/3uapRYr

Lysosomal Storage Diseases, Protein-Misfolding, Heat-Shock Protein, Orphan Diseases, Orphan Drugs, and Rare Disease